1.
Drugged Out: How Cognitive Bias Hurts Drug Innovation
51 San Diego Law Review 419 (2014)
Number of pages: 90
Posted: 01 Sep 2013
Last Revised: 09 Aug 2014
Accepted Paper Series
Loyola University of Chicago School of Law
Downloads
11,057
2.
The Effects of Service Quality and Word of Mouth on Customer Acquisition, Retention and Usage
Number of pages: 48
Posted: 11 Mar 2007
Working Paper Series
City University of Hong Kong, University of Michigan, Stephen M. Ross School of Business and University of Chicago
Downloads
3,831
3.
Unpatentable Drugs and the Standards of Patentability
Texas Law Review, Vol. 87, pp. 503-570, 2009
Number of pages: 68
Posted: 04 May 2008
Last Revised: 02 Jun 2013
Accepted Paper Series
MIT Sloan
Downloads
1,842
4.
The Great Global Vitamins Cartels
Number of pages: 190
Posted: 28 Feb 2006
Last Revised: 15 May 2008
Working Paper Series
Purdue University
Downloads
1,185
5.
The Doha Round's Public Health Legacy: Strategies for the Production and Diffusion of Patented Medicines Under the Amended TRIPS Provisions
Journal of International Economic Law, Vol. 10, pp. 921-87, 2007, FSU College of Law, Law and Economics Paper No. 07-25, FSU College of Law, Public Law Research Paper No. 287
Number of pages: 68
Posted: 01 Nov 2007
Last Revised: 01 May 2013
Accepted Paper Series
Florida State University - College of Law and Duke University School of Law
Downloads
1,026
6.
Has the European Commission Become More Severe in Punishing Cartels? Effects of the 2006 Guidelines
Number of pages: 26
Posted: 11 Jan 2011
Last Revised: 27 Jan 2011
Working Paper Series
Purdue University
Downloads
1,012
7.
Pioneering Advantage in Generic Drug Competition
International Journal of Pharmaceutical and Healthcare Marketing 01/2014; 8(2)
Number of pages: 51
Posted: 20 Aug 2006
Last Revised: 05 Sep 2014
Accepted Paper Series
AIG and Cornell University - Samuel Curtis Johnson Graduate School of Management
Downloads
999
8.
The Untold EpiPen Story: How Mylan Hiked Prices by Blocking Rivals
102 Cornell Law Review Online 53 (2017)
Number of pages: 20
Posted: 21 Sep 2016
Last Revised: 01 Feb 2017
Accepted Paper Series
Rutgers Law School and Independent
Downloads
999
9.
Pharmaceutical Development Phases: A Duration Analysis
FTC, Bureau of Economics Working Paper No. 274
Number of pages: 30
Posted: 25 Oct 2004
Working Paper Series
Global Economics Group, LLC, Federal Trade Commission - Bureau of Economics and Moody's Investors Service
Downloads
979
10.
Business Model Innovation in the Pharmaceutical Industry: The Supporting Role of Organizational Design
Number of pages: 32
Posted: 25 Feb 2014
Working Paper Series
Bocconi University - Department of Management and Technology and Copenhagen Business School
Downloads
934
11.
Patent Trolling — Why Bio & Pharmaceuticals Are at Risk
17 Stan. Tech. L. Rev. 773, 2014, UC Hastings Research Paper No. 93
Number of pages: 40
Posted: 15 Feb 2014
Last Revised: 03 Apr 2016
Accepted Paper Series
University of California Hastings College of the Law and University of Michigan Law School
Downloads
911
12.
Competition and Regulation Issues in the Pharmaceutical Industry
Org. for Economic Co-operation & Dev., Best Practice Roundtables in Competition Policy No. 32
Number of pages: 401
Posted: 30 Jul 2002
Working Paper Series
Australian Competition and Consumer Commission
Downloads
835
13.
Innovation for the 21st Century: Harnessing the Power of Intellectual Property and Antitrust Law
Oxford University Press, 2009
Number of pages: 16
Posted: 27 Mar 2009
Accepted Paper Series
Rutgers Law School
Downloads
781
14.
Asymmetric Social Interactions in Physician Prescription Behavior: The Role of Opinion Leaders
Stanford University Graduate School of Business Research Paper No. 1970
Number of pages: 41
Posted: 13 Oct 2006
Last Revised: 30 Jul 2014
Working Paper Series
Stanford University - Graduate School of Business, University of Michigan, Stephen M. Ross School of Business and Rutgers, The State University of New Jersey - Rutgers Business School at Newark & New Brunswick
Downloads
759
15.
Access to Information and the Right to Health: The Human Rights Case for Clinical Trials Transparency
American Journal of Law and Medicine, Vol. 38, pp. 63-112, 2012
Number of pages: 50
Posted: 27 Sep 2011
Last Revised: 06 Mar 2015
Accepted Paper Series
University of Toronto - Faculty of Law and Independent
Downloads
747
16.
Cartel Overcharges and Optimal Cartel Fines
Number of pages: 16
Posted: 16 Nov 2007
Last Revised: 20 Nov 2007
Working Paper Series
University of Baltimore - School of Law and Purdue University
There are 2 versions of this paper
Cartel Overcharges and Optimal Cartel Fines
Number of pages: 16
Posted: 16 Nov 2007
Last Revised: 20 Nov 2007
Downloads
742
Downloads
742
17.
Counterfeit Drugs: The Good, the Bad and the Ugly
Albany Law Journal of Science and Technology, Vol. 15, 2006
Number of pages: 15
Posted: 30 Aug 2006
Accepted Paper Series
Boston University School of Law and affiliation not provided to SSRN
Downloads
727
18.
Do National Patent Laws Stimulate Domestic Innovation in a Global Patenting Environment? A Cross-Country Analysis of Pharmaceutical Patent Protection, 1978-2002
Review of Economics and Statistics, Vol. 89, No. 3, 2007
Number of pages: 18
Posted: 28 Oct 2007
Last Revised: 08 Jun 2014
Accepted Paper Series
Downloads
725
19.
Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health
Journal of Law, Medicine and Ethics, Forthcoming
Number of pages: 30
Posted: 28 Jun 2013
Last Revised: 24 Oct 2015
Accepted Paper Series
Carleton University - School of Public Policy and Administration
Downloads
697
20.
Some Accounting and Technical Problems with Antidumping Trade Cases Involving a Transition Economy: A Russian Case Study
Number of pages: 15
Posted: 12 Sep 2003
Working Paper Series
Fayetteville State University - Department of Accounting and Abu Dhabi University - Department of Accounting
Downloads
693
21.
The Size of Cartel Overcharges: Implications for U.S. and E.U. Fining Policies
Number of pages: 40
Posted: 31 May 2007
Last Revised: 17 Sep 2008
Working Paper Series
Purdue University and University of Baltimore - School of Law
Downloads
681
22.
Countervailing Power in Wholesale Pharmaceuticals
MIT Dept. of Economics Working Paper No. 01-27
Number of pages: 40
Posted: 25 Jul 2001
Working Paper Series
Massachusetts Institute of Technology (MIT) - Department of Economics and Dartmouth College - Department of Economics
Downloads
672
23.
Synthesizing Law for Synthetic Biology
Minnesota Journal of Law, Science & Technology, Vol. 11, No. 2, pp. 629-65, 2010
Number of pages: 37
Posted: 25 Jun 2010
Accepted Paper Series
University of Kansas - School of Law
Downloads
666
24.
Pharmaceutical Marketing: Medical and Industry Biases
Journal of Pharmaceutical Finance, Economics & Policy, Forthcoming
Number of pages: 17
Posted: 04 Feb 2004
Accepted Paper Series
Emory University - Department of Economics
Downloads
661
25.
Heterogeneous Learning and the Targeting of Marketing Communication for New Products
Number of pages: 43
Posted: 12 Oct 2006
Working Paper Series
Stanford Graduate School of Business and University of Michigan, Stephen M. Ross School of Business
Downloads
659
26.
A Real-World Analysis of Pharmaceutical Settlements: The Missing Dimension of Product-Hopping
Florida Law Review, Vol. 62, 2010
Number of pages: 28
Posted: 14 Apr 2010
Last Revised: 28 Dec 2013
Working Paper Series
Rutgers Law School
Downloads
647
27.
Bidil: Race Medicine or Race Marketing?
Health Affairs, October 11, 2005
Number of pages: 9
Posted: 26 Oct 2005
Accepted Paper Series
University of Pennsylvania - Perelman School of Medicine and Mitchell Hamline School of Law
Downloads
646
28.
Two Puzzles Resolved: Of the Schumpeter - Arrow Stalemate and Pharmaceutical Innovation Markets
Iowa Law Review, Vol. 93, 2008
Number of pages: 58
Posted: 09 Apr 2007
Last Revised: 02 Jun 2013
Accepted Paper Series
Rutgers Law School
Downloads
646
29.
Using Antitrust Law to Challenge Turing's Daraprim Price Increase
31 Berkeley Technology Law Journal 1379 (2017)
Number of pages: 30
Posted: 29 Jan 2016
Last Revised: 14 Jul 2017
Accepted Paper Series
Rutgers Law School, Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics and Brigham and Women's Hospital/Harvard Medical School
Downloads
646
30.
Diversification Strategy in the Pharmaceutical Industry
Number of pages: 20
Posted: 14 Oct 2008
Working Paper Series
"Alexandru Ioan Cuza" University of Iasi, Romania
Downloads
641
31.
Consumer Protection in an Era of Globalization
IMPORT SAFETY: REGULATORY GOVERNANCE IN THE GLOBAL ECONOMY, Cary Coglianese, Adam Finkel & David Zaring, eds., University of Pennsylvania Press, 2009
, U of Penn, Inst for Law & Econ Research Paper No. 11-10
Number of pages: 20
Posted: 25 Mar 2011
Accepted Paper Series
University of Pennsylvania Law School, University of Michigan School of Public Health and University of Pennsylvania - Legal Studies Department
Downloads
635
32.
Effectiveness of Antitrust Sanctions on Modern International Cartels
Journal of Industry, Competition, and Trade 6 (2006): 195-223
Number of pages: 29
Posted: 31 May 2007
Last Revised: 09 Mar 2013
Accepted Paper Series
Purdue University
Downloads
620
33.
Marketing, Product Differentiation and Competition in the Market for Antiulcer Drugs
HBS Working Paper No. 01-014
Number of pages: 49
Posted: 23 Mar 2006
Working Paper Series
Greylock McKinnon Associates
Downloads
618
34.
The United States Department of Justice Antitrust Division's Cartel Enforcement: Appraisal and Proposals
American Antitrust Institute Working Paper No. 08-02
Number of pages: 93
Posted: 08 May 2008
Last Revised: 22 May 2009
Working Paper Series
Purdue University
Downloads
607
35.
REACHing Asia Continued
Number of pages: 13
Posted: 18 Sep 2009
Working Paper Series
Ghent University - Faculty of Law
Downloads
595
36.
Global Antitrust Prosecutions of International Cartels: Focus on Asia
Number of pages: 34
Posted: 07 Nov 2007
Last Revised: 20 Apr 2009
Working Paper Series
Purdue University
Downloads
585
37.
What is 'Business Development'? The Case of Biotechnology
Schmalenbach Business Review, Vol. 59, April 2007
Number of pages: 25
Posted: 04 Aug 2007
Accepted Paper Series
affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads
567
38.
Quantifying the Benefits of Individual Level Targeting in the Presence of Firm Strategic Behavior
Number of pages: 50
Posted: 17 Oct 2006
Working Paper Series
Santa Clara University - Marketing, University of Michigan, Stephen M. Ross School of Business and University of Chicago
Downloads
563
39.
The Indian Pharmaceutical Industry - Fundamentals vis-a-vis Market Perception
Number of pages: 23
Posted: 08 Mar 2009
Working Paper Series
Calcutta Business School and affiliation not provided to SSRN
Downloads
548
40.
Determinants of the Round-to-Round Returns to Pre-Ipo Venture Capital Investments in U.S. Biotechnology Companies
Number of pages: 44
Posted: 08 Jan 2004
Working Paper Series
University of North Carolina Kenan-Flagler Business School
Downloads
545
41.
Impact of Profitability, R&D Intensity, and Cash Flow on R&D Expenditure in Pharmaceutical Companies
Number of pages: 13
Posted: 05 May 2011
Working Paper Series
Dexa Laboratories of Biomolecular Sciences, Dexa Medica Group and Department of Business Development and Dexa Laboratories of Biomolecular Sciences, PT Dexa Medica
Downloads
539
42.
Do Reverse Payment Settlements Violate the Antitrust Laws?
Santa Clara Computer and High Technology Law Journal, Vol. 23, p. 489, 2007
Number of pages: 99
Posted: 30 May 2007
Accepted Paper Series
University of Missouri - Kansas City School of Law
Downloads
537
43.
Can Compulsory Licensing Improve Access to Essential Medicines?
Number of pages: 21
Posted: 23 Apr 2008
Working Paper Series
University of Connecticut - School of Business
Downloads
534
44.
Cartel Amnesties Granted: Worldwide Whistleblowers
Number of pages: 26
Posted: 21 Oct 2008
Working Paper Series
Purdue University
Downloads
531
45.
The Economic Sense of Royalty Rates
Number of pages: 5
Posted: 06 Aug 1997
Working Paper Series
Financial-Tip
Downloads
531
46.
Killer Acquisitions
Number of pages: 73
Posted: 12 Sep 2018
Last Revised: 22 Mar 2019
Working Paper Series
London Business School, Yale School of Management and Yale School of Management
Downloads
530
47.
Regulatory Exposure of Deceptive Marketing and its Impact on Firm Value
Journal of Marketing, 2009
Number of pages: 49
Posted: 11 Sep 2009
Accepted Paper Series
Independent, University of Georgia--Terry School of Business and University of Pennsylvania - Legal Studies Department
Downloads
529
48.
Unsettling Drug Patent Settlements: A Framework for Presumptive Illegality
Michigan Law Review, Vol. 108
Number of pages: 44
Posted: 11 Mar 2009
Last Revised: 05 May 2015
Accepted Paper Series
Rutgers Law School
Downloads
521
49.
Valuation of Intangible Assets: Estimating Late-Stage Development Cost of Pharmaceutical R&D
Number of pages: 52
Posted: 12 Sep 2007
Working Paper Series
Institute of Leadership and Management in Health - Kingston University and Henley Management College - Henley Centre for Value Improvement (HCVI)
Downloads
510
50.
New Drug Development: Estimating Entry from Human Clinical Trials
FTC Bureau of Economics Working Paper No. 262
Number of pages: 24
Posted: 12 Sep 2003
Working Paper Series
Federal Trade Commission - Bureau of Economics and Federal Trade Commission - Bureau of Economics
Downloads
503
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.